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Following publication of the original article \[[@CR1]\], the authors reported errors in Figures 2, 3 and Figure 3 'continued'.In Figure 2b and 2f of PDX2 model, duplicated pictures of tumors have been used.In Figure 3 of H&E staining of PDX-004, duplicated pictures have been used. Moreover, the description of the second PDX-001 was not correct in Figure 3.In Figure 3 'continued' of H&E staining, duplicated pictures have been used in all PDX groups. Moreover, the part labels in Figure 3 'continued' were not correct.

In this Correction the corrected version of Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"} and Fig. [3](#Fig3){ref-type="fig"} 'continued' are shown.Fig. 2Sensitivity of PDX models containing CDK4 aberrations to CDK4/6 inhibitors in vivo. When the tumor size reached approximately 600 mm^3^, mice (n = 4 per group) were treated with buffer control or inhibitors daily. Tumor volume was evaluated as % of the tumor volume on day 0 and presented as mean ± SD. The comparison of the growth curves was done with the repeated measure variance analysis. *ns* no significances; \*\*P \< 0.01; \*\*\*P \< 0.001Fig. 3Proliferation index of mucosal melanoma cells from PDX models containing CDK4 aberrations after CDK4/6 inhibitors treatments. On day 14 of treatments, the tumor nodules were excised and examined by H&E staining and immunohistochemical staining (for Ki-67). The sections were evaluated under microscope, and typical staining was photographed (**a**). The Ki-67 + cells under 5 random fields were counted. Bar = 20 μm. The results of Ki-67 + cells (**b**--**f**) were presented as mean ± SD of three sections. *ns* no significances; \*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001
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